CNN on MSN25d
Ozempic and Wegovy selected for next round of Medicare drug price negotiations
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...
Trump order signals shake-up in drug pricing innovation through Medicare and Medicaid
President Donald Trump’s Day One executive order rescinding Biden-era Medicare and Medicaid price innovation programs signals ...
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
RFK Jr. grilled on Medicare: What is Medicare Part A, Medicare Part B and Medicaid? What are they?
Senators grilled Robert F. Kennedy Jr. on if and how he would reform Medicaid and Medicare during his first confirmation ...
Insurer Denies Access To Drugs Granted Accelerated Approval By FDA
Going forward, we may see more instances in which insurers deny or (temporarily) severely restrict coverage of accelerated ...
How Medicare Says It Arrives At ‘Fair’ Prescription Drug Prices
We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it ...
Let Medicare cover weight loss drugs to make America healthy
If Robert F. Kennedy Jr. and the Trump administration want to make America healthy again, they should let Medicare cover ...
JD Supra12d
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval ...
Idaho Business Review6d
Health care sector gears up for the second Trump administration
Donald Trump’s second term brings major health care shifts with RFK Jr. leading HHS and deregulatory changes ahead. industry ...
Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.